Genetic Susceptibility to Kidney Cancer

Status Terminated

Clinical Trial Summary

This study will further the understanding of the genetic events leading to the development of RCC.

Clinical Trial Description

This study will further the understanding of the genetic events leading to the development of RCC; explore the genetic basis for genetic instability and how it affects cancer risk; and eventually provide a means of identifying a subgroup of individuals who are most likely to develop RCC. Such individuals may then be targeted for intervention programs such as chemoprevention or dietary modification. ;

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Renal Cell
Genetic Predisposition to Disease
Renal Cell Carcinoma

Clinical Trial Details

NCT number	NCT00854022
Study type	Observational
Source	Baylor College of Medicine
Contact
Status	Terminated
Phase
Start date	July 2008
Completion date	March 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04987203` - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma	Phase 3
Recruiting	`NCT06391879` - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed	`NCT02526017` - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers	Phase 1
Recruiting	`NCT05059444` - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated	`NCT03655613` - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC	Phase 1/Phase 2
Active, not recruiting	`NCT03170960` - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Withdrawn	`NCT05418387` - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona	N/A
Recruiting	`NCT04623502` - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	N/A
Completed	`NCT02853344` - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)	Phase 2
Terminated	`NCT04088500` - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma	Phase 2
Completed	`NCT05070637` - Circulating Tumor Cell Reducing No-touch Nephrectomy	N/A
Active, not recruiting	`NCT03634540` - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)	Phase 2
Not yet recruiting	`NCT06049030` - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 1
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Completed	`NCT01358721` - Phase I Biomarker Study (BMS-936558)	Phase 1
Active, not recruiting	`NCT04503148` - Anesthesia and Cancer Study: Renal Cell Carcinoma	N/A
Completed	`NCT02386826` - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme	Phase 1
Not yet recruiting	`NCT05808608` - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma	Phase 1/Phase 2
Withdrawn	`NCT03323710` - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma	Phase 2
Not yet recruiting	`NCT02787915` - DC1s-CTL Cellular Therapy for Renal Cell Carcinoma	Phase 1/Phase 2